The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”

References

• Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5–6):231–37. doi:10.1242/dmm.001180.
   PubMed Web of Science ®Google Scholar
• Yang H-Y, Wu C-Y, Powell JD, Lu K-L. Manipulation of metabolic pathways and its consequences for anti-tumor immunity: a clinical perspective. Int J Mol Sci. 2020 Jun 4;21(11):4030. doi:10.3390/ijms21114030.
   PubMed Web of Science ®Google Scholar
• Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7(1):12150. doi:10.1038/ncomms12150.
   PubMed Web of Science ®Google Scholar
• Safari E, Ghorghanlu S, Ahmadi-Khiavi H, Mehranfar S, Rezaei R, Motallebnezhad M. Myeloid-derived suppressor cells and tumor: current knowledge and future perspectives. J Cell Physiol. 2019;234(7):9966–81. doi:10.1002/jcp.27923.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015 Apr;14(4):847–56. doi:10.1158/1535-7163.MCT-14-0983.
   PubMed Web of Science ®Google Scholar
• Porta C, Marino A, Consonni FM, Bleve A, Mola S, Storto M, Riboldi E, Sica A. Metabolic influence on the differentiation of suppressive myeloid cells in cancer. Carcinogenesis. 2018;39(9):1095–104. doi:10.1093/carcin/bgy088.
   PubMed Web of Science ®Google Scholar
• Sica A, Strauss L. Energy metabolism drives myeloid-derived suppressor cell differentiation and functions in pathology. J Leukoc Biol. 2017;102(2):325–34. doi:10.1189/jlb.4MR1116-476R.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. doi:10.1038/nature07205.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–89. doi:10.1038/nature10673.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45. doi:10.1016/S0140-6736(00)04046-0.
   PubMed Web of Science ®Google Scholar
• Perrone F, Minari R, Bersanelli M, Bordi P, Tiseo M, Favari E, Sabato R, Buti S. The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors. J Immunother. 2020 Jul/Aug;43(6):196–203. doi:10.1097/CJI.0000000000000321.
   PubMed Web of Science ®Google Scholar
• Gautier EL, Huby T, Saint-Charles F, Ouzilleau B, Pirault J, Deswaerte V, Ginhoux F, Miller ER, Witztum JL, Chapman MJ. Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis. Circulation. 2009 May 5;119(17):2367–75. doi:10.1161/CIRCULATIONAHA.108.807537.
   PubMed Web of Science ®Google Scholar
• Bersanelli M, Leonetti A, Buti S. The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade. Immunotherapy. 2017 Nov;9(14):1127–31.
   PubMed Web of Science ®Google Scholar
• Poels K, van Leent MMT, Reiche ME, Kusters PJH, Huveneers S, de Winther MPJ, Mulder WJM, Lutgens E, Seijkens TTP. Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice. Cells. 2020 Aug 29;9(9):E1987. doi:10.3390/cells9091987.
   PubMed Web of Science ®Google Scholar
• Yang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, Meng X, Li L, Wang J, Xu C. Potentiating the antitumor response of CD8+ T cells by modulating cholesterol metabolism. Nature. 2016;531(7596):651–55. doi:10.1038/nature17412.
   PubMed Web of Science ®Google Scholar
• Fan Z, Liu H, Xue Y, Lin J, Fu Y, Xia Z, Pan D, Zhang J, Qiao K, Zhang Z, et al. Reversing cold tumors to hot: an immunoadjuvant-functionalized metal-organic framework for multimodal imaging-guided synergistic photo-immunotherapy. Bioact Mater. 2020 Aug 28;6(2):312–25. doi:10.1016/j.bioactmat.2020.08.005.
   PubMed Web of Science ®Google Scholar
• Janji B, Hasmim M, Parpal S, De Milito A, Berchem G, Noman MZ. Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34. Autophagy. 2020 Sep;5:1–2.
   Google Scholar
• Bersanelli M, Buti S. From targeting the tumor to targeting the immune system: transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol. 2017 Feb 10;8(1):37–53. doi:10.5306/wjco.v8.i1.37.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Chen L, Paradigm A. Shift in cancer immunotherapy: from enhancement to normalization. Cell. 2019 Jan 24;176(3):677. doi:10.1016/j.cell.2019.01.008.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM. Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016 Nov 10;375(19):1845–55. doi:10.1056/NEJMoa1611299.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627–39. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 Jul 9;373(2):123–35. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277–90. doi:10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017 Oct 5;377(14):1345–56. doi:10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823–33. doi:10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375(19):1856–67. doi:10.1056/NEJMoa1602252.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803–13.
   PubMed Web of Science ®Google Scholar
• Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén A. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020 Sep 24;383(13):1218–30. doi:10.1056/NEJMoa2002788.
   PubMed Web of Science ®Google Scholar
• Giròn-Ulloa A, Gonzàlez-Domìnguez E, Klimek RS, et al. Specific macrophage subsets accumulate in human subcutaneous and omental fat depots during obesity. Immunol Cell Biol. 2020 Jul 22. doi:10.1111/imcb.12380.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015 Apr;36(4):265–76. doi:10.1016/j.it.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Young AC, Quach HT, Song H, Davis EJ, Moslehi JJ, Ye F, Williams GR, Johnson DB. Impact of body composition on outcomes from anti-PD1 ± anti-CTLA-4 treatment in melanoma. J Immunother Cancer. 2020 Jul;8(2):e000821. doi:10.1136/jitc-2020-000821.
   PubMed Web of Science ®Google Scholar
• McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 Mar;19(3):310–22. doi:10.1016/S1470-2045(18)30078-0.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer. 2019;7(1):57. doi:10.1186/s40425-019-0527-y.
   PubMed Web of Science ®Google Scholar
• Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer—viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–98. doi:10.1056/NEJMsr1606602.
   PubMed Web of Science ®Google Scholar
• Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, Adami H-O, Lee JE, Lee HM. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer. 2013;132(3):625–34. doi:10.1002/ijc.27639.
   PubMed Web of Science ®Google Scholar
• Hakimi AA, Furberg H, Zabor EC, Jacobsen A, Schultz N, Ciriello G, Mikklineni N, Fiegoli B, Kim PH, Voss MH. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst. 2013;105(24):1862–70. doi:10.1093/jnci/djt310.
   PubMedGoogle Scholar
• Sanchez A, Furberg H, Kuo F, Vuong, L, Ged Y, Patil S, Ostrovnaya I, Petruzella S, Reising A, Patel P, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol. 2019 Dec 20. published online. doi:10.1016/S1470-2045(19)30797-1.
   Web of Science ®Google Scholar
• Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, et al. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. Eur J Cancer. 2020 Mar;128:17–26.
   PubMed Web of Science ®Google Scholar
• Centanni M, Moes DJAR, Troco´niz IF, Ciccolini J, van Hasselt JGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019;58(7):835e57. doi:10.1007/s40262-019-00748-2.
   Web of Science ®Google Scholar
• Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol. 2018. 10:1758835918764628. doi:10.1177/1758835918764628.
   Web of Science ®Google Scholar
• Bomze D, Hasan Ali O, Bate A, Flatz L. Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden [published online ahead of print, 2019 Aug 22]. JAMA Oncol. 2019;5(11):1633–35. doi:10.1001/jamaoncol.2019.3221.
   PubMed Web of Science ®Google Scholar
• Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer [published correction appears in JAMA Oncol. 2019 Jul 1;5(7):1070]. JAMA Oncol. 2019;5(7):1043–47. doi:10.1001/jamaoncol.2019.0402.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist. 2019 Jun;24(6):e327–e337. doi:10.1634/theoncologist.2018-0618.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Buti S, Agostinelli V, Bersanelli M. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Semin Oncol. 2019 Aug-Oct;46(4–5):362–71. Epub 2019 Nov 7. PMID: 31727344. doi:10.1053/j.seminoncol.2019.10.003.
   PubMed Web of Science ®Google Scholar
• Xingzhe M, Enguang B, Yong L, Su P, Huang C, Liu L, Wang Q, Yang M, Kalady MF, Qian J. Cholesterol induces CD8 + T cell exhaustion in the tumor microenvironment. Cell Metab. 2019 Jul 2;30(1):143–156.e5. doi:10.1016/j.cmet.2019.04.002.
   PubMed Web of Science ®Google Scholar
• Elahi S, Weiss RH, Merani S. Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS. 2016 Jan;30(2):171–83. doi:10.1097/QAD.0000000000000917.
   PubMed Web of Science ®Google Scholar